Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

NCT02182310 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 201335 low dose
DRUG: BI 201335 placebo
DRUG: Moxifloxacin
DRUG: BI 201335 high dose

Sponsor

Boehringer Ingelheim